# Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI

> **NCT06343064** · PHASE1,PHASE2 · RECRUITING · sponsor: **Avistone Biotechnology Co., Ltd.** · enrollment: 156 (estimated)

## Conditions studied

- Non-Small-Cell Lung Cancer

## Interventions

- **DRUG:** Vebreltinib
- **DRUG:** PLB1004

## Key facts

- **NCT ID:** NCT06343064
- **Lead sponsor:** Avistone Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-13
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 156 (ESTIMATED)
- **Last updated:** 2025-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06343064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06343064, "Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06343064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*